Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
about
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonistEnteric microbiome metabolites correlate with response to simvastatin treatmentForty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysisPitavastatin in cardiometabolic disease: therapeutic profileA comprehensive review on metabolic syndromeMetabolomics reveals amino acids contribute to variation in response to simvastatin treatmentIschemic heart disease in women: a focus on risk factorsStatins for primary prevention of venous thromboembolismHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisStatins for preventing colorectal adenoma and carcinomaHMG CoA reductase inhibitors (statins) for kidney transplant recipientsStatins for the primary prevention of cardiovascular diseaseStatins for aortic valve stenosisStatins for primary prevention of venous thromboembolismStatins for the primary prevention of cardiovascular diseaseThe cycle of bias in health research: a framework and toolbox for critical appraisal trainingFibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap)Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapyRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveStatin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanismColesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of actionC-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection StudyOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskEfficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysisJupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Are statins diabetogenic?Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: a cross sectional studyAspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsGenetic Loci associated with C-reactive protein levels and risk of coronary heart diseaseInhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levelsStabilization of high-risk plaquesHuman Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsRecent advances in pathogenesis, assessment, and treatment of atherosclerosisStatin-induced diabetes: incidence, mechanisms, and implicationsThe role of inflammation in cardiovascular diseases: the predictive value of neutrophil-lymphocyte ratio as a marker in peripheral arterial diseaseWhat happens to cardiovascular system behind the undetectable level of HIV viremia?Management of intracerebral hemorrhage--use of statinsCETP Inhibition: Past Failures and Future Hopes2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension
P2860
Q21132391-F2B45C5F-86E5-4014-B6A1-2FF6DEA65C8AQ21135141-AAF37D36-449E-43D3-ADC1-BD72785CE289Q21144992-3BCC44F9-0B64-4869-A394-1C9F0CEAFA95Q21246037-ECA64E4F-D577-40CF-99A0-61D8368077C9Q21284500-570FFAA7-F78F-4E0D-B198-9D6D907C5AD6Q21561017-1EFB8A90-A25A-47F0-9CA0-397E0F08F37FQ22251459-99638928-CD39-4202-BC6C-BE11AEA0607CQ24187238-46F047A6-A374-4477-9AB5-C91BEDE5D13CQ24194514-493C0FFC-2F5D-4CF8-A31E-A55993BB310DQ24194802-167BD65E-9A49-4D18-A9C9-9A471D908D81Q24200984-C7C58C2C-2E7E-49CD-925F-E864ED8B6A2AQ24201513-7D89DE34-82F9-4C43-94EC-1FF5CD1ED96EQ24203993-3892D303-F0F9-456E-A673-3ED9AA605FB1Q24204040-73E764A8-7F60-408F-8318-E3A61D8FB524Q24234813-7AEA8A66-176A-4C76-B39B-17A84B825DABQ24289237-5436ACA9-084A-4BE6-8FC2-1C6830DB89DBQ24306597-3AA42FB0-CD84-47BD-A3D8-0D3454845F7CQ24594496-B6BD152F-9265-4BD7-82DE-794E3F522AA5Q24594814-F480A914-DC16-4455-8734-2980EA719187Q24602803-E59C53BE-E12C-4FEC-9AC1-491EBFAFC0B0Q24603957-819EC899-D091-4DEA-A399-8109620CBC1FQ24613405-E30319D6-050F-43F9-A30D-9E820E6495E6Q24617734-72DFC83E-56B4-4825-B87C-DCA17FEA38D3Q24626884-C156BEF6-DADF-4418-998F-A24A5C4C735CQ24628361-0EC740C1-8886-4BA3-91CE-5AA1EC018DDBQ24630160-9AF4B3E8-FB30-45CE-8772-9B966EF5C408Q24630205-DFE3B5CA-AE6B-457D-9121-82AAFD3D6D66Q24633407-402EBC39-F910-4827-8DD2-B0801040F630Q24645391-1A03DFF2-676B-40F9-8E97-F69C29F7AE53Q24649709-09BB82DB-52A9-43ED-BB96-240F13374DF8Q24658351-5ECD7974-DFC9-4F14-B891-D390941E873CQ26738584-464EC8C2-ABCA-4216-B73A-7691E1335708Q26740117-F5B8B76C-71F7-4086-AFFC-2FF91CD55EA8Q26740304-B417DA38-BD32-4C1F-84E3-64818CDB2C86Q26740677-B7FF6738-9D4F-48B1-8012-BD1A3EB0893AQ26745592-7B5E7198-72E0-47C4-A4B8-603EB524821EQ26749024-1290B6FD-3D51-49DD-A72B-D5BFB1649508Q26752952-67080D47-B061-4EDB-8A60-FADCBEB08644Q26753158-3A068008-1E24-4EF8-9937-B19DECE78C21Q26764784-71E1E610-AD0D-4063-A487-59C5CAC0AE7C
P2860
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@ast
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@en
type
label
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@ast
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@en
prefLabel
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@ast
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@en
P2093
P3181
P356
P1476
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
@en
P2093
Danielson E
Fonseca FA
Gotto AM Jr
Kastelein JJ
Lorenzatti AJ
MacFadyen JG
P304
P3181
P356
10.1056/NEJMOA0807646
P407
P577
2008-11-20T00:00:00Z